News & Updates
Filter by Specialty:
Add-on brivaracetam for epilepsy makes good in real-world practice
Long-term postmarketing data for adjunctive brivaracetam show that its use helps improve seizure control in patients with various epilepsy syndromes, even in those with prior exposure to levetiracetam. However, psychobehavioural adverse events (AEs) occur in one out of ten patients.
Add-on brivaracetam for epilepsy makes good in real-world practice
02 Nov 2021
Transplantation bias, misconceptions endure for alcohol-, obesity-related liver disease
Bias and misconceptions about liver transplantation persist for patients with alcohol- (ALD) and obesity-related liver disease (OLD), a study has found.
Transplantation bias, misconceptions endure for alcohol-, obesity-related liver disease
02 Nov 2021
Omission of parametrial boost does not compromise local control, survival in modern era
Leaving out the use of external beam parametrial boost (EBPB) for locally advanced cervical cancer does not seem to negatively affect local control or survival in the era of image-guided brachytherapy, results of a study have shown. This then supports a reduced need for standardized use of parametrial boost.
Omission of parametrial boost does not compromise local control, survival in modern era
02 Nov 2021
Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?
In individuals receiving disease-modifying antirheumatic drugs* (DMARDs) for inflammatory rheumatic diseases** (IRD), humoral response remained satisfactory following administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2, a study suggests.
Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?
02 Nov 2021
Hepatic arterial infusion chemo improves OS vs TACE in large HCC
Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin and oxaliplatin (FOLFOX) as first-line treatment significantly improves overall survival (OS) vs transarterial chemoembolization (TACE) in patients with large, unresectable hepatocellular carcinoma (HCC), a phase III trial in China has shown.
Hepatic arterial infusion chemo improves OS vs TACE in large HCC
02 Nov 2021
Antigliadin IgG spots IBS patients who benefit from gluten-free diet
Some patients with irritable bowel syndrome (IBS) may achieve symptom reduction, particularly diarrhoea, on a gluten-free diet, and who these patients are may be identified by using the antigliadin immunoglobulin G (IgG) as a biomarker, according to a study.
Antigliadin IgG spots IBS patients who benefit from gluten-free diet
02 Nov 2021
Even within normal levels, high FPG increases risk of type 2 diabetes
Among healthy individuals, a fasting plasma glucose (FPG) concentration within the range of 90–99 mg/dL increases the risk of type 2 diabetes, a new Japan study has found.
Even within normal levels, high FPG increases risk of type 2 diabetes
02 Nov 2021
Bevacizumab reduces need for vitrectomy in PDR patients with vitreous haemorrhage
Intravitreal bevacizumab (IVB) injections induce short-lived visual benefit but ease the need for vitrectomy in proliferative diabetic retinopathy (PDR) patients with vitreous haemorrhage (VH) who had undergone prior complete panretinal photocoagulation (PRP), a recent study has found.
